Top ▲
Target not currently curated in GtoImmuPdb
Target id: 3094
Nomenclature: hydroxysteroid 17-beta dehydrogenase 2
Family: 1.-.-.- Oxidoreductases
Gene and Protein Information | ||||||
Species | TM | AA | Chromosomal Location | Gene Symbol | Gene Name | Reference |
Human | 1 | 387 | 16q23.3 | HSD17B2 | hydroxysteroid 17-beta dehydrogenase 2 | |
Mouse | 1 | 381 | 8 E1 | Hsd17b2 | hydroxysteroid (17-beta) dehydrogenase 2 | |
Rat | - | 381 | 19q12 | Hsd17b2 | hydroxysteroid (17-beta) dehydrogenase 2 |
Previous and Unofficial Names |
17β-HSD2 | estradiol 17-beta-dehydrogenase 2 | HSD17 | SDR9C2 | short chain dehydrogenase/reductase family 9C, member 2 |
Database Links | |
Alphafold | P37059 (Hs), P51658 (Mm) |
BRENDA | 1.1.1.62, 1.1.1.239 |
ChEMBL Target | CHEMBL2789 (Hs), CHEMBL1914270 (Mm) |
Ensembl Gene | ENSG00000086696 (Hs), ENSMUSG00000031844 (Mm), ENSRNOG00000013982 (Rn) |
Entrez Gene | 3294 (Hs), 15486 (Mm), 79243 (Rn) |
Human Protein Atlas | ENSG00000086696 (Hs) |
KEGG Enzyme | 1.1.1.62, 1.1.1.239 |
KEGG Gene | hsa:3294 (Hs), mmu:15486 (Mm), rno:79243 (Rn) |
OMIM | 109685 (Hs) |
Pharos | P37059 (Hs) |
RefSeq Nucleotide | NM_002153 (Hs), NM_008290 (Mm), NM_024391 (Rn) |
RefSeq Protein | NP_002144 (Hs), NP_032316 (Mm), NP_077367 (Rn) |
UniProtKB | P37059 (Hs), P51658 (Mm) |
Wikipedia | HSD17B2 (Hs) |
Enzyme Reaction | ||||||||
|
Download all structure-activity data for this target as a CSV file
Inhibitors | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Key to terms and symbols | View all chemical structures | Click column headers to sort | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
View species-specific inhibitor tables |
General Comments |
17β-HSD2 catalyses the interconversion of estradiol <-> estrone and testosterone <-> androstenedione. Pharmacological inhibition of 17β-HSD2 is being investigated as a novel mechanism for the treatment of osteoporosis. Inhibiting 17β-HSD2 is predicted to increase estradiol and testosterone levels in bone, and to thereby simultaneously inhibit osteoclast-mediated bone resorption and increase bone formation by osteoblasts. |
1. Abdelsamie AS, Salah M, Siebenbürger L, Merabet A, Scheuer C, Frotscher M, Müller ST, Zierau O, Vollmer G, Menger MD et al.. (2019) Design, Synthesis, and Biological Characterization of Orally Active 17β-Hydroxysteroid Dehydrogenase Type 2 Inhibitors Targeting the Prevention of Osteoporosis. J Med Chem, 62 (15): 7289-7301. [PMID:31343176]
1.-.-.- Oxidoreductases: hydroxysteroid 17-beta dehydrogenase 2. Last modified on 26/07/2019. Accessed on 19/01/2025. IUPHAR/BPS Guide to PHARMACOLOGY, https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3094.